Pharma
How Eli Lilly’s oral GLP-1 could change the obesity drug market
A hot new GLP-1 bombshell has entered the villa.
Therapeutic Areas & Drug Cases
Deep dives into Therapeutic Areas & Drug Cases and its impact on healthcare. From Mifepristone and Women's Health Drugs to industry-wide shifts, Healthcare Brew covers the essential developments in Pharma.
Pharma
Pfizer, Novo Nordisk bidding war is just the latest escalation of a lucrative GLP-1 race
The G in GLP-1 might as well stand for gold.
Pharma
Healthcare execs on the state of psychedelic medicine
While there’s still a long way to go, the industry is starting to embrace psychedelics.
Pharma
Serena Williams as Ro’s celeb ambassador could mark ‘a big shift’ in pharma advertising
Pharma isn’t known for big-name celebrity appearances, but Ro’s approach could change the landscape.
Pharma
What’s the difference between the GLP-1s on the market?
From semaglutide vs. tirzepatide to Ozempic vs. Wegovy.
Pharma
Eli Lilly, Novo Nordisk report strong earnings as GLP-1 race heats up
Both drugmakers saw strong YoY sales, though Novo’s GLP-1 sales were down slightly from Q4 2024.
Pharma
What’s next for GLP-1s?
Because who doesn’t prefer swallowing a pill over getting a shot?
Navigate the healthcare industry
Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed.
By subscribing, you accept our Terms & Privacy Policy.
